PMID: 7523993May 23, 1994Paper

Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra

Neuroscience Letters
L NaudonJ Costentin

Abstract

[3H]dihydrotetrabenazine ([3H]TBZOH) was used to label the monoamine vesicular transporter in the rat substantia nigra. An accumulation of neuronal vesicles in the substantia nigra pars compacta was observed after blockade of the fast axonal transport by a microinjection of colchicine (10 micrograms/2 microliters) into the medial forebrain bundle. This accumulation was measured after sustained 2-day pharmacological modifications of the central dopaminergic transmission. It was not modified after s.c. administration of either the direct dopamine (DA) receptor agonist bromocriptine (four injections of 4 or 6 mg/kg) or the DA receptor antagonist haloperidol (four injections of 0.5-1-1.5-2 mg/kg). Thus, it appears that these pharmacological modifications, imposed to the activity of the nigro-striatal dopaminergic system during 2 days, have no consequence on the rate of synthesis of its vesicles.

References

Jul 30, 1975·Naunyn-Schmiedeberg's Archives of Pharmacology·B ScattonL Julou
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·E J NestlerR S Duman
Apr 12, 1989·European Journal of Pharmacology·H L WienerH Sershen
Jan 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D SchermanJ P Henry
May 1, 1993·The European Journal of Neuroscience·D LechardeurP M Laduron

❮ Previous
Next ❯

Citations

Apr 1, 2003·Annals of Neurology·David J Brooks
Dec 1, 1996·Annals of Neurology·K A FreyD E Kuhl
Feb 24, 2007·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Nicolaas I Bohnen, Kirk A Frey
Dec 29, 1995·European Journal of Pharmacology·T Vander BorghtK Frey
Feb 7, 2002·Neurotoxicology·T R Guilarte
Nov 14, 2002·Neurotoxicology·Maria E ReveronGary W Miller
May 15, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Moshe RehaviAbraham Weizman
Jul 20, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michal ZuckerMoshe Rehavi
Nov 14, 1997·Nuclear Medicine and Biology·M R Kilbourn
Nov 1, 1996·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·R A KoeppeD E Kuhl
Oct 6, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·R A KoeppeD E Kuhl
Feb 4, 2010·Nuclear Medicine and Biology·Michael R KilbournKirk A Frey
Jan 20, 2006·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Nicolaas I BohnenKirk A Frey
Mar 26, 2005·Brain Research. Molecular Brain Research·Wing Lok AuA Jon Stoessl
Dec 14, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Erkki Tupala, Jari Tiihonen
Sep 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karin SchwartzMoshe Rehavi
Feb 2, 2008·Annals of Neurology·W R Wayne MartinMichael Schulzer
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David S SegalArthur K Cho
Oct 26, 2018·Scientific Reports·Thea P LillethorupAnne M Landau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here